Aclaris Therapeutics, Inc. (ACRS)
| Market Cap | 837.59M |
| Revenue (ttm) | 6.84M |
| Net Income (ttm) | -81.23M |
| Shares Out | 61.23M |
| EPS (ttm) | -1.55 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 299,057 |
| Open | 13.30 |
| Previous Close | 13.22 |
| Day's Range | 13.13 - 13.71 |
| 52-Week Range | 3.48 - 30.38 |
| Beta | 0.46 |
| Analysts | Strong Buy |
| Price Target | 34.80 (+154.4%) |
| Earnings Date | Nov 3, 2021 |
About ACRS
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel, small molecule therapeutics to address the needs of patients with immuno-inflammatory diseases. The company has a multi-stage portfolio of drug candidates powered by a research and development engine exploring protein kinase regulation. Its products pipeline includes ATI-450, an investigational oral, novel, small molecule selective MK2 inhibitor compound, which is being developed as a treatment for moderate to severe rheumatoid arthritis and...
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for ACRS stock is "Strong Buy." The 12-month stock price forecast is 34.80, which is an increase of 154.39% from the latest price.
News
Aclaris Therapeutics Announces Publication of Preclinical Research of Zunsemetinib in Pancreatic Cancer in Science Tr...
WAYNE, Pa., Dec. 03, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory di...
Aclaris Therapeutics to Host Virtual R&D Day on December 7, 2021
Investigational New Drug Application for ATI-2138 Allowed
Aclaris Therapeutics to Participate in Upcoming Investor Conferences
WAYNE, Pa., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory di...
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Lags Revenue Estimates
Aclaris (ACRS) delivered earnings and revenue surprises of -29.63% and -9.05%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Aclaris Therapeutics Reports Third Quarter 2021 Financial Results and Provides a Corporate Update
WAYNE, Pa., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory di...
Analysts Estimate Aclaris Therapeutics (ACRS) to Report a Decline in Earnings: What to Look Out for
Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aclaris Therapeutics Announces Proposed Settlement and Settlement Hearing of Stockholder Derivative Action
WAYNE, Pa., Aug. 27, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory di...
Should You Buy Aclaris Therapeutics (ACRS) Ahead of Earnings?
Aclaris Therapeutics (ACRS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Aclaris Therapeutics Reports Second Quarter 2021 Financial Results and Provides a Corporate Update
WAYNE, Pa., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory di...
Aclaris Therapeutics (ACRS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Aclaris (ACRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aclaris Announces Pricing of Public Offering of Common Stock
WAYNE, Pa., June 09, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory dis...
Aclaris (ACRS) Announces Data on Atopic Dermatitis Candidate
Aclaris (ACRS) reports encouraging preliminary top-line results from a phase IIa study evaluating its JAK 1/3 inhibitor, ATI-1777, for the treatment of moderate to severe atopic dermatitis.
Aclaris Announces Proposed Public Offering of Common Stock
WAYNE, Pa., June 08, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory di...
Aclaris' ATI-1777 Aces Atopic Dermatitis Trial with Minimal Systemic Exposure
Aclaris Therapeutics Inc (NASDAQ: ACRS) has announced preliminary topline results from its Phase 2a trial evaluating ATI-1777 for moderate to severe atopic dermatitis (AD). The primary efficacy endpoint...
Aclaris Therapeutics to Participate in the Jefferies Virtual Healthcare Conference
WAYNE, Pa., May 17, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory dis...
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue Estimates
Aclaris (ACRS) delivered earnings and revenue surprises of -111.11% and 20.72%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Aclaris Therapeutics Reports First Quarter 2021 Financial Results and Provides a Corporate Update
WAYNE, Pa., May 07, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory dis...
Aclaris Therapeutics (ACRS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aclaris Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare Conference
WAYNE, Pa., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory di...
Aclaris (ACRS) Up on Preliminary Data for MK2 Inhibitor in RA
Aclaris (ACRS) posts favorable preliminary topline results from a phase IIa study evaluating its investigational oral candidate ATI-450 for treating moderate to severe rheumatoid arthritis. Shares up.
Why Aclaris Therapeutics Stock Skyrocketed More Than 200% Today
Investors are excited about the biotech's clinical trial results.
ACRS Stock Alert: Why Aclaris Therapeutics Is Up Over 200% Today
Aclaris Therapeutics (ACRS) stock is soaring higher on Tuesday after revealing results from a recent Phase 2a clinical trial. The post ACRS Stock Alert: Why Aclaris Therapeutics Is Up Over 200% Today ap...
Why Aclaris, Tenax, Gritstone, Merus, Minerva And Celyad Are Rallying Today
A slew of biopharma stocks are making big moves Tuesday on the back of clinical trial readouts as well announcements regarding M&A and tie-ups. Merus, Lilly In $1.68B Oncology Deal: Dutch-based Merus NV...
Implied Volatility Surging for Aclaris Therapeutics (ACRS) Stock Options
Investors need to pay close attention to Aclaris Therapeutics (ACRS) stock based on the movements in the options market lately.
Aclaris Therapeutics Announces Formation of New Scientific Advisory Board
WAYNE, Pa., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory di...